Premium
Therapeutic decision‐making in inhibitor patients
Author(s) -
Allen Geoffrey,
Aledort Louis
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20474
Subject(s) - medicine , dosing , intensive care medicine , selection (genetic algorithm) , surgery , computer science , artificial intelligence
Abstract A panel of hematologists met to discuss treatment choices in patients with hemophilia A and inhibitors. The group agreed that the management of bleeding episodes is complicated by a variable response to bypassing therapy, uncertainties regarding optimal dosing of NovoSeven, and concerns about the combined use of NovoSeven and FEIBA. Thrombotic risk was rated very low for both agents, and there was consensus that product selection should not be restricted to recombinant products. Cost considerations in therapeutic decision‐making were also discussed. Am. J. Hematol. 81:71–72, 2006. © 2005 Wiley‐Liss, Inc.